An agent that blocks the release of adrenergic transmitters and may have other actions. It was formerly used as an antihypertensive agent, but is now proposed as an anti-arrhythmic.
Bretylium compounds are a class of drugs used in the medical field to treat certain types of heart arrhythmias by blocking the influx of calcium ions into cardiac cells.
The TEMPERATURE at the outer surface of the body.
An indole-dione that is obtained by oxidation of indigo blue. It is a MONOAMINE OXIDASE INHIBITOR and high levels have been found in urine of PARKINSONISM patients.
The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.
An antidepressive agent that has also been used in the treatment of movement disorders. The mechanism of action is not well understood.
Unstable isotopes of fluorine that decay or disintegrate emitting radiation. F atoms with atomic weights 17, 18, and 20-22 are radioactive fluorine isotopes.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.
A voluntary organization concerned with the prevention and treatment of heart and vascular diseases.
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
The thoracolumbar division of the autonomic nervous system. Sympathetic preganglionic fibers originate in neurons of the intermediolateral column of the spinal cord and project to the paravertebral and prevertebral ganglia, which in turn project to target organs. The sympathetic nervous system mediates the body's response to stressful situations, i.e., the fight or flight reactions. It often acts reciprocally to the parasympathetic system.

Aerobic training and cutaneous vasodilation in young and older men. (1/30)

To determine the effect and underlying mechanisms of exercise training and the influence of age on the skin blood flow (SkBF) response to exercise in a hot environment, 22 young (Y; 18-30 yr) and 21 older (O; 61-78 yr) men were assigned to 16 wk of aerobic (A; YA, n = 8; OA, n = 11), resistance (R; YR, n = 7; OR, n = 3), or no training (C; YC, n = 7; OC, n = 7). Before and after treatment, subjects exercised at 60% of maximum oxygen consumption (VO2 max) on a cycle ergometer for 60 min at 36 degrees C. Cutaneous vascular conductance, defined as SkBF divided by mean arterial pressure, was monitored at control (vasoconstriction intact) and bretylium-treated (vasoconstriction blocked) sites on the forearm using laser-Doppler flowmetry. Forearm vascular conductance was calculated as forearm blood flow (venous occlusion plethysmography) divided by mean arterial pressure. Esophageal and skin temperatures were recorded. Only aerobic training (functionally defined a priori as a 5% or greater increase in VO2 max) produced a decrease in the mean body temperature threshold for increasing forearm vascular conductance (36.89 +/- 0.08 to 36.63 +/- 0.08 degrees C, P < 0.003) and cutaneous vascular conductance (36.91 +/- 0.08 to 36.65 +/- 0.08 degrees C, P < 0.004). Similar thresholds between control and bretylium-treated sites indicated that the decrease was mediated through the active vasodilator system. This shift was more pronounced in the older men who presented greater training-induced increases in VO2 max than did the young men (22 and 9%, respectively). In summary, older men improved their SkBF response to exercise-heat stress through the effect of aerobic training on the cutaneous vasodilator system.  (+info)

Baroreceptor modulation of active cutaneous vasodilation during dynamic exercise in humans. (2/30)

The hypothesis that baroreceptor unloading during dynamic limits cutaneous vasodilation by withdrawal of active vasodilator activity was tested in seven human subjects. Increases in forearm skin blood flow (laser-Doppler velocimetry) at skin sites with (control) and without alpha-adrenergic vasoconstrictor activity (vasodilator only) and in arterial blood pressure (noninvasive) were measured and used to calculate cutaneous vascular conductance (CVC). Subjects performed two similar dynamic exercise (119 +/- 8 W) protocols with and without baroreceptor unloading induced by application of -40 mmHg lower body negative pressure (LBNP). The LBNP condition was reversed (i.e., either removed or applied) after 15 min while exercise continued for an additional 15 min. During exercise without LBNP, the increase in body core temperature (esophageal temperature) required to elicit active cutaneous vasodilation averaged 0.25 +/- 0.08 and 0.31 +/- 0.10 degrees C (SE) at control and vasodilator-only skin sites, respectively, and increased to 0.44 +/- 0.10 and 0.50 +/- 0.10 degrees C (P < 0.05 compared with without LBNP) during exercise with LBNP. During exercise baroreceptor unloading delayed the onset of cutaneous vasodilation and limited peak CVC at vasodilator-only skin sites. These data support the hypothesis that during exercise baroreceptor unloading modulates active cutaneous vasodilation.  (+info)

Gradation of the reflex response from atrial receptors. (3/30)

1. In anaesthetized dogs, distension of balloons so as to stimulate atrial receptors resulted in a reflex increase in heart rate. 2. Successive distensions of one, two and three balloons positioned in the left upper and middle pulmonary vein-atrial junctions and in the left atrial appendage resulted in a progressive increase in the magnitude of this response. 3. It is concluded that the magnitude of the increase in heart rate is related to the extent of receptor area stimulated.  (+info)

Neurogenic sympathetic vasoconstriction of the rabbit basilar artery. (4/30)

When examined by fluorescence microscopy the rabbit basilar artery contains a rich adrenergic-like plexus at the adventitiomedial junction. The fluorescence disappears upon chronic reserpinization and bilateral superior cervical ganglionectomy. Transmural stimulation of intramural nerves a results in a response which is predominantly constrictor but also contains a small, inconstant dilator component. The constrictor response is abolished by chronic reserpinization, bilateral superior cervical ganglionectomy, and cold storage of the preparation. The constriction is prevented by the adrenergic neuron blocking agents guanethidine and bretylium but not by such alpha-adrenergic receptor blocking agents as phenoxybenzamine (PBZ), phentolamine, and tolazoline. Our results show that doses of the three latter agents sufficient to abolish contractions to norepinephrine (NE) in concentrations of up to 10(-2) M only potentiate and prolong the contractile response to nerve stimulation. The beta-adrenergic receptor blocking agent, propranolol, and inhibitors of NE neuronal uptake, such as desipramine (desmethylimipramine, DMI) and cocaine, do not influence the size of the neurogenic response. These results suggest that the vasoconstrictor component of the rabbit basilar artery response to transmural nerve stimulation (TNS) is mediated via sympathetic adrenergic-like neurons, but at the same time also raise the question whether the transmission process is typical of classic adrenergic neuroeffector mechanisms.  (+info)

Cutaneous active vasodilation in humans during passive heating postexercise. (5/30)

The hypothesis that exercise causes an increase in the postexercise esophageal temperature threshold for onset of cutaneous vasodilation through an alteration of active vasodilator activity was tested in nine subjects. Increases in forearm skin blood flow and arterial blood pressure were measured and used to calculate cutaneous vascular conductance at two superficial forearm sites: one with intact alpha-adrenergic vasoconstrictor activity (untreated) and one infused with bretylium tosylate (bretylium treated). Subjects remained seated resting for 15 min (no-exercise) or performed 15 min of treadmill running at either 55, 70, or 85% of peak oxygen consumption followed by 20 min of seated recovery. A liquid-conditioned suit was used to increase mean skin temperature ( approximately 4.0 degrees C/h), while local forearm temperature was clamped at 34 degrees C, until cutaneous vasodilation. No differences in the postexercise threshold for cutaneous vasodilation between untreated and bretylium-treated sites were observed for either the no-exercise or exercise trials. Exercise resulted in an increase in the postexercise threshold for cutaneous vasodilation of 0.19 +/- 0.01, 0.39 +/- 0.02, and 0.53 +/- 0.02 degrees C above those of the no-exercise resting values for the untreated site (P < 0.05). Similarly, there was an increase of 0.20 +/- 0.01, 0.37 +/- 0.02, and 0.53 +/- 0.02 degrees C for the treated site for the 55, 70, and 85% exercise trials, respectively (P < 0.05). It is concluded that reflex activity associated with the postexercise increase in the onset threshold for cutaneous vasodilation is more likely mediated through an alteration of active vasodilator activity rather than through adrenergic vasoconstrictor activity.  (+info)

The effects of ventricular end-diastolic and systolic pressures on action potential and duration in anaesthetized dogs. (6/30)

1. Although it is known that mechanical events in the heart influence the duration of the cardiac action potential, there is no quantitative information on the effects of independent changes in ventricular end-diastolic and systolic pressures. 2. Experiments were carried out on open-chest anaesthetized dogs in which the autonomic nervous influences on the heart were prevented and monophasic action potentials were recorded form the epicardial surface of the left ventricle. The duration of these action potentials was taken as the interval from the upstroke to the point of 90% repolarization. 3. Elevation of left ventricular peak systolic pressure, at constant end-diastolic pressure, significantly shortened the monophasic action potential. 4. Elevation of end-diastolic pressure at constant peak systolic pressure significantly lengthened the monophasic action potential. 5. Responses were not dependent on release of noradrenaline from sympathetic nerve terminals because they persisted after administration of bretylium tosylate. They were also not due to myocardial ischaemia because they persisted when coronary perfusion pressure was maintained at a constant high level. 6. Simultaneous recordings of changes in myocardial segment length showed the expected responses to changes in ventricular pressures: increases in shortening in response to increases in diastolic pressure and no consistent effect from changes in systolic pressure. 7. These investigations demonstrate the independent effects of changes in systolic and end-diastolic pressures on cardiac action potential duration. This effect is likely to be an effect of the mechanical events, i.e. contraction-excitation feedback. This response may be mediated through changes in myocardial fibre tension, the consequent changes in fibre shortening, or both.  (+info)

Sympathetic, sensory, and nonneuronal contributions to the cutaneous vasoconstrictor response to local cooling. (7/30)

Previous work indicates that sympathetic nerves participate in the vascular responses to direct cooling of the skin in humans. We evaluated this hypothesis further in a four-part series by measuring changes in cutaneous vascular conductance (CVC) from forearm skin locally cooled from 34 to 29 degrees C for 30 min. In part 1, bretylium tosylate reversed the initial vasoconstriction (-14 +/- 6.6% control CVC, first 5 min) to one of vasodilation (+19.7 +/- 7.7%) but did not affect the response at 30 min (-30.6 +/- 9% control, -38.9 +/- 6.9% bretylium; both P < 0.05, P > 0.05 between treatments). In part 2, yohimbine and propranolol (YP) also reversed the initial vasoconstriction (-14.3 +/- 4.2% control) to vasodilation (+26.3 +/- 12.1% YP), without a significant effect on the 30-min response (-26.7 +/- 6.1% YP, -43.2 +/- 6.5% control; both P < 0.05, P > 0.05 between sites). In part 3, the NPY Y1 receptor antagonist BIBP 3226 had no significant effect on either phase of vasoconstriction (P > 0.05 between sites both times). In part 4, sensory nerve blockade by anesthetic cream (Emla) also reversed the initial vasoconstriction (-20.1 +/- 6.4% control) to one of vasodilation (+213.4 +/- 87.0% Emla), whereas the final levels did not differ significantly (-37.7 +/- 10.1% control, -37.2 +/- 8.7% Emla; both P < 0.05, P > 0.05 between treatments). These results indicate that local cooling causes cold-sensitive afferents to activate sympathetic nerves to release norepinephrine, leading to a local cutaneous vasoconstriction that masks a nonneurogenic vasodilation. Later, a vasoconstriction develops with or without functional sensory or sympathetic nerves.  (+info)

Delayed threshold for active cutaneous vasodilation in patients with Type 2 diabetes mellitus. (8/30)

Epidemiological evidence suggests decreased heat tolerance in patients with Type 2 diabetes mellitus (T2DM), but it is not known whether the mechanisms involved in thermoregulatory control of skin blood flow are altered in these patients. We tested the hypothesis that individuals with T2DM have a delayed internal temperature threshold for active cutaneous vasodilation during whole body heating compared with healthy control subjects. We measured skin blood flow using laser-Doppler flowmetry (LDF), internal temperature (T or) via sublingual thermocouple, and mean arterial pressure via Finometer at baseline and during whole body heating in 9 T2DM patients and 10 control subjects of similar age, height, and weight. At one LDF site, sympathetic noradrenergic neurotransmission was blocked by local pretreatment with bretylium tosylate (BT) to isolate the cutaneous active vasodilator system. Whole body heating was conducted using a water-perfused suit. There were no differences in preheating T(or) between groups (P > 0.10). Patients with T2DM exhibited an increased internal temperature threshold for the onset of vasodilation at both untreated and BT-treated sites. At BT-treated sites, T or thresholds were 36.28 +/- 0.07 degrees C in controls and 36.55 +/- 0.05 degrees C in T2DM patients (P < 0.05), indicating delayed onset of active vasodilation in patients. Sensitivity of vasodilation was variable in both groups, with no consistent difference between groups (P > 0.05). We conclude that altered control of active cutaneous vasodilation may contribute to impaired thermoregulation in patients with T2DM.  (+info)

Bretylium tosylate is a medication that is used to treat certain types of abnormal heart rhythms, such as atrial fibrillation and ventricular tachycardia. It works by blocking the electrical signals that cause the heart to beat irregularly. Bretylium tosylate is typically given intravenously in a hospital setting, and it can cause serious side effects, such as low blood pressure, rapid heart rate, and difficulty breathing. It is not suitable for everyone and should only be used under the supervision of a healthcare professional.

Bretylium compounds are a class of drugs that are used in the medical field to treat certain types of heart arrhythmias, such as atrial fibrillation and ventricular tachycardia. These drugs work by blocking the influx of certain ions, such as sodium and calcium, into cardiac muscle cells, which can help to stabilize the heart rhythm and prevent further arrhythmias from occurring. Bretylium compounds are typically administered intravenously and are used as a last resort when other treatments have failed or are not appropriate. They can cause a number of side effects, including nausea, vomiting, and low blood pressure, and may interact with other medications that are being taken.

Isatin, also known as 1H-indole-2,3-dione, is a chemical compound that is commonly used in the medical field as a research tool and as a starting material for the synthesis of other compounds. It is a white solid that is soluble in water and organic solvents. In the medical field, isatin has been studied for its potential therapeutic effects in a variety of conditions, including cancer, inflammation, and neurodegenerative diseases. It has been shown to have anti-inflammatory and anti-cancer properties, and it may also have potential as an antioxidant and anti-aging agent. Isatin has also been used in the development of new drugs and as a tool for studying the mechanisms of action of other drugs. For example, it has been used to study the effects of certain drugs on the activity of enzymes and receptors in the body. Overall, isatin is a versatile compound with a wide range of potential applications in the medical field, and ongoing research is exploring its potential as a therapeutic agent and as a tool for understanding the underlying mechanisms of various diseases.

Guanethidine is a medication that is used to treat high blood pressure (hypertension) and pheochromocytoma, a rare tumor of the adrenal gland. It works by blocking the production of norepinephrine, a hormone that causes blood vessels to narrow and blood pressure to rise. Guanethidine is typically taken by mouth and is usually given in combination with other medications to treat hypertension. It may also be used to treat other conditions, such as Raynaud's disease, which is a condition that causes the blood vessels in the fingers and toes to narrow, leading to pain and discoloration. Guanethidine can cause side effects, such as dizziness, headache, and low blood pressure, and should be used with caution in people with certain medical conditions, such as heart disease or diabetes.

I'm sorry, but I couldn't find any information on a medical term called "Deanol." It's possible that you may have misspelled the term or that it is not a recognized medical term. If you have any additional information or context, please let me know and I'll do my best to assist you.

Fluorine radioisotopes are radioactive isotopes of the element fluorine that are used in medical imaging and treatment. These isotopes are typically produced in a cyclotron or other particle accelerator and are then introduced into the body, where they can be detected and imaged using specialized equipment. Fluorine radioisotopes are used in a variety of medical applications, including: 1. Positron emission tomography (PET) scans: Fluorine-18 is a commonly used radioisotope in PET scans, which are used to image the body's metabolism and assess the function of organs such as the brain, heart, and lungs. 2. Fluoride therapy: Fluorine-18 is also used in fluoride therapy, which is a treatment for osteoporosis and other bone diseases. In this treatment, patients are given a solution containing fluorine-18, which is absorbed by the bones and helps to strengthen them. 3. Radiosynovectomy: Fluorine-18 is also used in radiosynovectomy, a treatment for rheumatoid arthritis. In this treatment, a solution containing fluorine-18 is injected into the affected joint, where it is absorbed by the inflamed synovial tissue and destroys it. Fluorine radioisotopes are generally considered safe when used in medical applications, but they can be harmful if they are ingested or inhaled in large quantities. As a result, special precautions are taken to ensure that patients are exposed to minimal amounts of these isotopes during medical procedures.

Hypotension is a medical condition characterized by low blood pressure. Blood pressure is the force exerted by the blood against the walls of the arteries as the heart pumps blood. It is measured in millimeters of mercury (mmHg) and is typically expressed as two numbers, systolic pressure (the pressure when the heart beats) and diastolic pressure (the pressure when the heart is at rest between beats). Hypotension is defined as a systolic blood pressure below 90 mmHg or a diastolic blood pressure below 60 mmHg. In some cases, a lower blood pressure may be considered normal or even desirable, depending on the individual's age, health status, and other factors. Hypotension can be caused by a variety of factors, including dehydration, medication side effects, heart problems, blood loss, and certain medical conditions such as diabetes, kidney disease, and hormonal imbalances. Symptoms of hypotension may include dizziness, lightheadedness, fainting, and fatigue. Treatment for hypotension depends on the underlying cause and may include medications, lifestyle changes, or medical procedures.

The American Heart Association (AHA) is a non-profit organization that is dedicated to promoting cardiovascular health and preventing heart disease and stroke. The AHA was founded in 1924 and is headquartered in Dallas, Texas. The AHA conducts research, develops guidelines and policies, and provides education and training to healthcare professionals and the public on topics related to heart disease, stroke, and other cardiovascular conditions. The organization also advocates for public policies that promote cardiovascular health and works to raise awareness about the importance of healthy lifestyle choices, such as regular physical activity, a healthy diet, and not smoking. The AHA's research and guidelines are widely respected in the medical field and are often used as the basis for clinical practice recommendations. The organization also publishes a number of well-known medical journals, including Circulation and Circulation Research.

Anti-arrhythmia agents, also known as anti-arrhythmic drugs, are medications that are used to treat abnormal heart rhythms, or arrhythmias. These medications work by affecting the electrical activity of the heart, either by slowing down or speeding up the heart rate, or by stabilizing the heart's rhythm. There are several different types of anti-arrhythmia agents, including class I, II, III, and IV drugs. Each class of drug works in a different way to affect the heart's electrical activity, and the choice of medication will depend on the specific type and severity of the arrhythmia being treated. Some common examples of anti-arrhythmia agents include beta blockers, calcium channel blockers, and sodium channel blockers. These medications can be used to treat a wide range of arrhythmias, including atrial fibrillation, ventricular tachycardia, and supraventricular tachycardia. It is important to note that anti-arrhythmia agents can have side effects, and their use should be closely monitored by a healthcare provider. In some cases, alternative treatments, such as electrical cardioversion or catheter ablation, may be necessary.

... (also bretylium tosylate) is an antiarrhythmic agent. It blocks the release of noradrenaline from nerve terminals. In ... On June 8, 2011 bretylium tosylate was announced as unavailable in the US after request of Hospira Inc. to withdraw its NDA ... US 3441649, Marvin B Bacaner, "Suppression of cardiac ventricular fibrillation and cardiac arrhythmias with bretylium tosylate ... Hypothermia~treatment at eMedicine "Determination that Bretylium Tosylate Injection, 50 Milligrams/Milliliter, Was Not ...
... bretylium compounds MeSH D02.092.877.096.333.150 - bretylium tosylate MeSH D02.092.877.233 - betalains MeSH D02.092.877.233.500 ... bretylium compounds MeSH D02.675.276.175.150 - bretylium tosylate MeSH D02.675.276.190 - cetrimonium compounds MeSH D02.675. ...
Bretylium (also bretylium tosylate) is an antiarrhythmic agent. It blocks the release of noradrenaline from nerve terminals. In ... On June 8, 2011 bretylium tosylate was announced as unavailable in the US after request of Hospira Inc. to withdraw its NDA ... US 3441649, Marvin B Bacaner, "Suppression of cardiac ventricular fibrillation and cardiac arrhythmias with bretylium tosylate ... Hypothermia~treatment at eMedicine "Determination that Bretylium Tosylate Injection, 50 Milligrams/Milliliter, Was Not ...
Use of bretylium tosylate as prophylaxis and treatment in hypothermic ventricular fibrillation in the canine model. Ann Emerg ... Prevention of ventricular fibrillation during hypothermia with bretylium tosylate. Anesth Analg. 1971 Jul-Aug. 50(4):587-93. [ ...
Ventricular arrhythmias dosing for bretylium, frequency-based adverse effects, comprehensive interactions, contraindications, ... bretylium tosylate injection. - 50 mg/mL vial. Copyright © 2010 First DataBank, Inc. ... encoded search term (bretylium (bretylium)) and bretylium (bretylium) What to Read Next on Medscape ... ponesimod, bretylium. Either increases effects of the other by QTc interval. Use Caution/Monitor. Consult cardiologist if ...
56] used bretylium tosylate to block the local release of norepinephrine on the forearm skin. They suggested that the ...
BRETYLIUM TOSYLATE 60265 BUPRENEX 60270 BUSPAR 60290 CAPOZIDE 60295 CEFOTAN 60325 CITRUCEL 60355 COLYTE 60370 CORDARONE 60385 ... BRETYLIUM 50668 BRILLIANT BLUE 50670 BRILLIANT GREEN 50675 BROMELAINS 50679 BROMINE 50680 BROMOCRIPTINE 50685 ...
BRETYLIUM TOSYLATE. May 10, 1980. 6505-01-094-4613. PENTYLENETETRAZOL A. May 10, 1980. ...
Reserpine bretylium tosylate. Executive Summary Interaction profiles of the prepara- unnecessary validation mismo y cialis ...
Use of bretylium tosylate as prophylaxis and treatment in hypothermic ventricular fibrillation in the canine model. Ann Emerg ... Prevention of ventricular fibrillation during hypothermia with bretylium tosylate. Anesth Analg. 1971 Jul-Aug. 50(4):587-93. [ ...
... blenoxane bleomycin sulfate bleph-10 bleph-30 blephamide blocadren bontril pdm borofair brethine bretylium tosylate 173 74 page ...
Bretylium Compounds D2.675.276.175 Bretylium Tosylate D2.675.276.175.150 Brimonidine Tartrate D3.438.857.70 D3.633.100.857.70 ...
Bretylium Compounds D2.675.276.175 Bretylium Tosylate D2.675.276.175.150 Brimonidine Tartrate D3.438.857.70 D3.633.100.857.70 ...
Bretylium Compounds D2.675.276.175 Bretylium Tosylate D2.675.276.175.150 Brimonidine Tartrate D3.438.857.70 D3.633.100.857.70 ...
Bretylium Compounds D2.675.276.175 Bretylium Tosylate D2.675.276.175.150 Brimonidine Tartrate D3.438.857.70 D3.633.100.857.70 ...
Bretylium Compounds D2.675.276.175 Bretylium Tosylate D2.675.276.175.150 Brimonidine Tartrate D3.438.857.70 D3.633.100.857.70 ...
BRETYLIUM TOSYLATE. BREVIBLOC. BREVICON. BREVITAL SODIUM. BREVITAL SODIUM FOR INJECTION, USP. BREVOXYL. BREVOXYL ACNE WASH KIT ...
Detailed drug Information for Limbitrol. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
A 39-year-old woman with long QT interval syndrome received chronic oral bretylium tosylate during pregnancy and subsequent ... Oral bretylium tosylate use during pregnancy and subsequent breastfeeding: a case report M Gutgesell 1 , E Overholt, R Boyle ... Oral bretylium tosylate use during pregnancy and subsequent breastfeeding: a case report M Gutgesell et al. Am J Perinatol. ... Bretylium tosylate: a review. Bryan CK, Darby MH. Bryan CK, et al. Am J Hosp Pharm. 1979 Sep;36(9):1189-92. Am J Hosp Pharm. ...
Use of bretylium tosylate as prophylaxis and treatment in hypothermic ventricular fibrillation in the canine model. Ann Emerg ... Prevention of ventricular fibrillation during hypothermia with bretylium tosylate. Anesth Analg. 1971 Jul-Aug. 50(4):587-93. [ ...
Because there is little published experience with bretylium during breastfeeding, its high frequency of side effects, and its ... Bretylium tosylate versus lidocaine in experimental cardiac arrest.[Am J Emerg Med. 1990]. Bretylium tosylate versus lidocaine ... Oral bretylium tosylate use during pregnancy and subsequent breastfeeding: a case report.[Am J Perinatol. 1990]. Oral bretylium ... A dose of 400 mg of bretylium tosylate every 8 hours was taken orally by one mother while nursing a newborn. She was also ...
Bretylium Tosylate,N0000006102, Turpentine,N0000006103, Selenium,N0000006104, gallium chloride,N0000006105, Pilocarpine, ... Bretylium Compounds,N0000007589, Pyrimidinones,N0000007588, Pyrimidines,N0000007587, Biogenic Monoamines,N0000007586, Amino ...
BRETYLIUM TOSYLATE. BRINZOLAMIDE. BROMHEXINE HYDROCHLORIDE. BROMOCRIPTINE MESYLATE. BROMPHENIRAMINE MALEATE. BROXYQUINOLINE. ...
Bretylium Compounds D2.675.276.175 Bretylium Tosylate D2.675.276.175.150 Brimonidine Tartrate D3.438.857.70 D3.633.100.857.70 ...
Bretylium Tosylate Preferred Term Term UI T005557. Date01/01/1999. LexicalTag NON. ThesaurusID ... Bretylium Tosylate Preferred Concept UI. M0002920. Registry Number. 78ZP3YR353. Related Numbers. 61-75-6. Scope Note. An agent ... Bretylium Compounds (1969-1975). Public MeSH Note. 91; was see under BRETYLIUM COMPOUNDS 1976-90. History Note. 91(76); was see ... Bretylium Tosylate. Tree Number(s). D02.092.877.096.333.150. Unique ID. D001950. RDF Unique Identifier. http://id.nlm.nih.gov/ ...
Bretylium Tosylate Preferred Term Term UI T005557. Date01/01/1999. LexicalTag NON. ThesaurusID ... Bretylium Tosylate Preferred Concept UI. M0002920. Registry Number. 78ZP3YR353. Related Numbers. 61-75-6. Scope Note. An agent ... Bretylium Compounds (1969-1975). Public MeSH Note. 91; was see under BRETYLIUM COMPOUNDS 1976-90. History Note. 91(76); was see ... Bretylium Tosylate. Tree Number(s). D02.092.877.096.333.150. Unique ID. D001950. RDF Unique Identifier. http://id.nlm.nih.gov/ ...
Bretylium tosilate Current Synonym true false 1237009010 Bretylium tosylate Current Synonym true false ...
Freis provided an overview of how bretylium tosylate and guanethidine acted to treat hypertension, but due to the dearth of ... Bretylium & Guanethidine: Two New Drugs Producing Specific Blockade of the Sympathetic Nervous System. body { margin: 0; ... Bretylium & Guanethidine: Two New Drugs Producing Specific Blockade of the Sympathetic Nervous System Creator:. Freis, Edward D ... Hypertension, Antihypertensive Agents, Guanethidine, and Bretylium Compounds Format:. Text Extent:. 2 pages Language:. English ...
Ventricular arrhythmias dosing for bretylium, frequency-based adverse effects, comprehensive interactions, contraindications, ... bretylium tosylate injection. - 50 mg/mL vial. Copyright © 2010 First DataBank, Inc. ... encoded search term (bretylium (bretylium)) and bretylium (bretylium) What to Read Next on Medscape ... ponesimod, bretylium. Either increases effects of the other by QTc interval. Use Caution/Monitor. Consult cardiologist if ...
... bretylium tosylate, E0300607,Ornid,bretylium tosylate, E0300611,Lexotan,bromazepam, E0300612,Lexotanil,bromazepam, E0300614, ...
... tosylate At about the same time that findings with guanethi- dine were announced a group of British investigators ... Dotiery, C. T., et al.: Bretylium Tosylate in the Treatment of Hypertension, Lancet 1:296 (Feb. 6) 1960. Frouuicyu, E. D., and ... There- fore, in ambulatory patients it has been found to be Chemical Structure of Guanethidine and Bretylium Tosylate 7 NH - ... The British compound is bretylium tosylate (Darenthin®). The American drug is guanethidine (Ismelin®). Both agents seem to ...
Use of bretylium tosylate as prophylaxis and treatment in hypothermic ventricular fibrillation in the canine model. Ann Emerg ... Prevention of ventricular fibrillation during hypothermia with bretylium tosylate. Anesth Analg. 1971 Jul-Aug. 50(4):587-93. [ ...
ANI Pharmaceuticals Announces Launch of Bretylium Tosylate Injection, USP 50 mg/mL. Dec 18, 2019. ...
Bretylate (Bretylium Tosylate) * Brevibloc (Esmolol HCl) * Blocadren (Timolol Maleate) * Bonamine (Meclizine HCl) ...
Benzylammonium compounds with the formula Br-phenyl-CN+R3 that include BRETYLIUM TOSYLATE. ... Benzylammonium compounds with the formula Br-phenyl-CN+R3 that include BRETYLIUM TOSYLATE.. ... Bretylium Compounds - Preferred Concept UI. M0002919. Scope note. ...
MedChemExpress Bretylium (tosylate) Orthodox Christian Muslim Protestant Ethnicity Guraghe Amhara Marital status (n = 449) ...
Freis provided an overview of how bretylium tosylate and guanethidine acted to treat hypertension, but due to the dearth of ... Bretylium Compounds. Genre(s):. Archival Materials. Articles. Abstract:. In this brief article, intended to acquaint practicing ... Bretylium & Guanethidine: Two New Drugs Producing Specific Blockade of the Sympathetic Nervous System. Contributor(s):. The ...
ANTI-ARRHYTHMIA AGENTS BRETYLIUM TOSYLATE ANTI-ARRHYTHMIA AGENTS BUNAFTINE ANTI-ARRHYTHMIA AGENTS BUPRANOLOL ANTI-ARRHYTHMIA ... ADRENERGIC AGENTS BRETYLIUM TOSYLATE ADRENERGIC AGENTS BUPRANOLOL ADRENERGIC AGENTS BUTOXAMINE ADRENERGIC AGENTS CARTEOLOL ... CARDIOVASCULAR AGENTS BRETYLIUM TOSYLATE CARDIOVASCULAR AGENTS BRINOLASE CARDIOVASCULAR AGENTS BUNAFTINE CARDIOVASCULAR AGENTS ... ADRENERGIC ANTAGONISTS BRETYLIUM TOSYLATE ADRENERGIC ANTAGONISTS BUPRANOLOL ADRENERGIC ANTAGONISTS BUTOXAMINE ADRENERGIC ...
Freis provided an overview of how bretylium tosylate and guanethidine acted to treat hypertension, but due to the dearth of ... Bretylium & Guanethidine: Two New Drugs Producing Specific Blockade of the Sympathetic Nervous System Digital Record ... Freis, Edward D. "Bretylium & Guanethidine: Two New Drugs Producing Specific Blockade of the Sympathetic Nervous System." The ... Bretylium & Guanethidine: Two New Drugs Producing Specific Blockade of the Sympathetic Nervous System, 101584929X34. Archives ...
Bretylium Compounds D2.675.276.175 Bretylium Tosylate D2.675.276.175.150 Brimonidine Tartrate D3.438.857.70 D3.633.100.857.70 ...
Bretylium Tosylate,. Darunavir Hydrate,. Darunavir N-Propanolate,. Darunavir Process II,. Mizolastine,. Safinamide,. Toldimfos ...
  • US 3441649, Marvin B Bacaner, "Suppression of cardiac ventricular fibrillation and cardiac arrhythmias with bretylium tosylate", assigned to University of Minnesota Khan, M. Gabriel (December 14, 2005). (wikipedia.org)
  • Benzylammonium compounds with the formula Br-phenyl-CN+R3 that include BRETYLIUM TOSYLATE. (bvsalud.org)
  • Bretylium tosylate: profile of the only available class III antiarrhythmic agent. (nih.gov)
  • Bretylium (also bretylium tosylate) is an antiarrhythmic agent. (wikipedia.org)
  • Hyperthermia associated with bretylium tosylate injection. (nih.gov)
  • In this brief article, intended to acquaint practicing physicians with several new ganglionic blocking agents, Freis provided an overview of how bretylium tosylate and guanethidine acted to treat hypertension, but due to the dearth of clinical testing on these relatively new drugs, did not provide many details as to their effectiveness. (nih.gov)
  • BRETYLIUM & GUANETHIDINE Two New Drugs Producing Specific Blockade of the Sympathetic Nervous System EDWARD D. FREIS, M.D. Senior Medical Investigator, Veterans Administra- tion Hospital, Washington, D.C. The purpose of this communication is to acquaint practicing physicians with a new class of antihyper- tensive agents. (nih.gov)
  • There- fore, in ambulatory patients it has been found to be Chemical Structure of Guanethidine and Bretylium Tosylate 7 NH - CH2- CH2 - NHC Hz S04 \NH2 2 {2-(octahydro-1-azocinyl)-ethyl] guanidine sulfate, guanethidine. (nih.gov)
  • bretylium tosylate At about the same time that findings with guanethi- dine were announced a group of British investigators published their report that bretylium tosylate, a com- pound which is chemically wholly different from guanethidine, also produced selective block of the sympathetic nervous system. (nih.gov)
  • US 3441649, Marvin B Bacaner, "Suppression of cardiac ventricular fibrillation and cardiac arrhythmias with bretylium tosylate", assigned to University of Minnesota Khan, M. Gabriel (December 14, 2005). (wikipedia.org)
  • Bretylium tosylate versus lidocaine in experimental cardiac arrest. (nih.gov)
  • Profound hypotension following a "test dose" of bretylium tosylate. (nih.gov)
  • A dose of 400 mg of bretylium tosylate every 8 hours was taken orally by one mother while nursing a newborn. (nih.gov)
  • The distribution of some quaternary ammonium salts in the peripheral nervous system of cats in relation to the adrenergic blocking action of bretylium. (nih.gov)
  • Bretylium will remain on the FDA's discontinued drug list since its withdrawal was not the result of a safety or effectiveness concern. (wikipedia.org)
  • Clinical trials of bretylium first in England and then in this country indicated that the drug produced pre- dominantly a postural hypotension and that it was free of the side effects of parasympathetic blockade. (nih.gov)